How many years can you survive taking gilteritinib?

Gilteritinib is a Flt-3 inhibitor, used to treat patients with relapsed or refractory acute myeloid leukemia (AML) who carry Flt-3 mutations. Giritinibhas a good therapeutic effect on acute refractory acute myeloid leukemia with FLT3 mutation, and it needs to be taken until the patient cannot benefit or has intolerable side effects. Giritinib can prolong the life of patients, but patients have different physiques and conditions, and there is no definite data on how long it can prolong life.

Relevant data show that in patients with relapsed or refractoryFLT3mutatedAML, geritinib significantly prolongs the survival time, and the percentage of patients who respond is higher than that of salvage treatment. After treatment, the median OS was 9.3 months and 5.6 months, respectively. The one-year survival rate for patients treated with giritinib was 37%, while the one-year survival rate for patients treated with salvage chemotherapy was 17%.

The half-life of geritinib is 113 hours, and the estimated apparent clearance rate is 14.85l/ hours. Giritinib is metabolized in vitro mainly through CYP3A4. Under steady state, the main metabolites in the human body include M17 ( formed through N-dealkylation and oxidation), M16and M10 (both formed by N-dealkylation ). None of these 3 metabolites exceeded 10% of the total maternal exposure. It is not known whether severe hepatic impairment (Child-Pugh C grade) or severe renal impairment(CLCr ≤ 29 mL/min)Effects on the pharmacokinetics of giritinib. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.